Showing results (221-230 of 253) with videos related to

Sort By:
Pageof 26
Neuropsychobiology|June 15, 2026
Clinicians' Preferences and Attitudes Toward the Use of Lithium in the Treatment of Bipolar Disorders in MexicoCarlos Arnaud-Gil, Manuel Sánchez de Carmona, Bernardo Ng, et al.
ACS Nano|April 3, 2020
Strongly Coupled Coherent Phonons in Single-Layer MoS2Chiara Trovatello, Henrique P C Miranda, Alejandro Molina-Sánchez, et al.
Dermatology and Therapy|March 9, 2023
Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective StudyPablo Fernandez-Crehuet, Sofía Haselgruber, Alicia Padial-Gomez, et al.
The Lancet. Oncology|April 12, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trialAna Oaknin, Kathleen Moore, Tim Meyer, et al.
Frontiers in Genetics|February 1, 2024
Epigenetic mechanisms of particulate matter exposure: air pollution and hazards on human healthDulcemaría Gavito-Covarrubias, Ivonne Ramírez-Díaz, Josué Guzmán-Linares, et al.
International Journal of Dermatology|April 15, 2026
Limited Effectiveness of IL-17 Inhibitors for Anti-TNF-Induced Psoriasis in Hidradenitis Suppurativa: A Multicenter Retrospective StudyLeonardo Bascón, Juan José Lluch-Galcerá, Verónica Mora-Fernández, et al.
Journal of Cutaneous Medicine and Surgery|June 3, 2026
Clinical Features of Hidradenitis Suppurativa in Down Syndrome Patients: A Multicenter Spanish StudyMaria Sin-Soler, Patricia Garbayo-Salmons, María Olivares-Guerrero, et al.
Dermatology and Therapy|August 27, 2025
Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated with Complete ResponseMiguel Mansilla-Polo, Carmen García-Moronta, Pablo Fernández-Crehuet, et al.
The Lancet. Oncology|February 6, 2019
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S Fuchs, Kohei Shitara, Maria Di Bartolomeo, et al.
The Australasian Journal of Dermatology|June 19, 2024
Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational studyMiguel Mansilla-Polo, Martí Pons-Benavent, Pablo Fernández-Crehuet, et al.
Pageof 26